GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.While investors closely watch year-over-year changes in headline numbers -- revenue and earni ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The company's unaudited financial statements for Q1 2024 show key balance sheet, operations, equity, and cash flow data [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $1.45 billion while stockholders' equity declined to $631.1 million due to stock repurchases | (in thousands) | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $533,295 | $672,296 | | Total current assets | $732,799 | $872,790 | | Total assets | $1,453,963 | $1,588,800 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $116,521 | $122,559 | | Total liabilities | $822,894 | $826,842 | | Total stockholders' equity | $631,069 | $761,958 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 revenue grew to $197.9 million, but operating income fell to $7.4 million, with an improved net loss of $1.0 million | (in thousands, except per share amounts) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Revenue | $197,880 | $183,986 | | Total costs and operating expenses | $190,499 | $172,683 | | Operating income | $7,381 | $11,303 | | Net loss | $(1,009) | $(3,290) | | Loss per share: Basic and diluted | $(0.00) | $(0.01) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' equity decreased by $130.9 million to $631.1 million, primarily due to $154.8 million in stock repurchases - The company repurchased **21.3 million shares** of Class A common stock for **$154.8 million** during the three months ended March 31, 2024[21](index=21&type=chunk)[71](index=71&type=chunk) - Of the total repurchases, **20.9 million shares** were bought back from related parties (Spectrum and Francisco Partners) for an aggregate consideration of **$151.4 million**[22](index=22&type=chunk)[70](index=70&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow increased to $42.6 million, but significant financing outflows led to a $139.0 million net decrease in cash | (in thousands) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $42,586 | $32,288 | | Net cash used in investing activities | $(20,615) | $(14,288) | | Net cash used in financing activities | $(160,972) | $(14,090) | | Net change in cash and cash equivalents | $(139,001) | $3,910 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes highlight customer concentration, a $27.5 million legal accrual, a new stock repurchase program, and revenue stream performance - For Q1 2024, **one customer accounted for 12% of revenue**; for Q1 2023, two customers accounted for 13% and 11% of revenue, respectively[40](index=40&type=chunk) - The company increased its accrued legal settlement to **$27.5 million** as of March 31, 2024, related to ongoing class action lawsuits concerning consumer privacy[47](index=47&type=chunk)[63](index=63&type=chunk) - In February 2024, the Board approved a new stock repurchase program authorizing up to **$450.0 million** of Class A common stock, with **$295.2 million remaining available** as of March 31, 2024[68](index=68&type=chunk) | (in thousands) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Prescription transactions revenue | $145,395 | $134,907 | | Subscription revenue | $22,601 | $24,143 | | Pharma manufacturer solutions revenue | $24,509 | $20,435 | | Other revenue | $5,375 | $4,501 | | **Total revenue** | **$197,880** | **$183,986** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=14&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses an 8% revenue increase, improved net loss, growth in Adjusted EBITDA, and key operational metrics for Q1 2024 [Key Financial and Operating Metrics](index=15&type=section&id=Key%20Financial%20and%20Operating%20Metrics) Monthly Active Consumers grew to 6.7 million while subscription plans declined; Adjusted EBITDA increased to $62.8 million | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Monthly Active Consumers (millions) | 6.7 | 6.1 | | Subscription plans (thousands) | 778 | 1,007 | | Non-GAAP Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Adjusted EBITDA | $62.8 million | $53.2 million | | Adjusted EBITDA Margin | 31.7% | 28.9% | [Results of Operations](index=18&type=section&id=Results%20of%20Operations) Revenue grew 8% driven by prescription and pharma solutions, while operating expenses rose due to a legal settlement accrual - Prescription transactions revenue **grew 8% YoY**, driven by a **10% increase in Monthly Active Consumers**[99](index=99&type=chunk)[100](index=100&type=chunk) - Pharma manufacturer solutions revenue **increased 20% YoY** due to organic growth and expanded market penetration[102](index=102&type=chunk) - Subscription revenue **decreased 6% YoY**, primarily due to the anticipated sunset of the Kroger Savings program[101](index=101&type=chunk) - General and administrative expenses **increased by $11.5 million (39%)**, mainly due to a **$13.0 million estimated legal settlement loss** recognized in the quarter[106](index=106&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with $533.3 million in cash, despite significant cash use for stock repurchases - The company's principal sources of liquidity as of March 31, 2024, were **$533.3 million in cash and cash equivalents** and **$91.7 million available** under its revolving credit facility[112](index=112&type=chunk) - Net cash used in financing activities **increased by $146.9 million** year-over-year, primarily driven by a **$143.7 million increase** in payments for stock repurchases[120](index=120&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=21&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Market risk exposures remain materially unchanged from the 2023 Annual Report on Form 10-K - There have been **no material changes** in the company's market risk since the disclosure in the 2023 10-K[123](index=123&type=chunk) [Controls and Procedures](index=21&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls in Q1 2024 - Management concluded that as of March 31, 2024, the company's **disclosure controls and procedures were effective**[124](index=124&type=chunk) - There were **no changes in internal control over financial reporting** during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[125](index=125&type=chunk) [PART II. OTHER INFORMATION](index=21&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=21&type=section&id=Item%201.%20Legal%20Proceedings) The company details a $28.0 million accrual for privacy lawsuits and a new securities class action lawsuit filed in April 2024 - The company accrued an estimated probable loss of **$28.0 million** as of March 31, 2024, for ongoing consumer privacy class action lawsuits[63](index=63&type=chunk) - A **new class action lawsuit** was filed on April 22, 2024, alleging violations of the Exchange Act related to the company's disclosures about a "grocer issue" that occurred in 2022[64](index=64&type=chunk) [Risk Factors](index=21&type=section&id=Item%201A.%20Risk%20Factors) Risk factors remain materially unchanged from those disclosed in the 2023 Annual Report on Form 10-K - There have been **no material changes** to the risk factors previously disclosed in the 2023 10-K[128](index=128&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=21&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details its Q1 2024 stock repurchases of $154.8 million and the remaining use of IPO proceeds - As of March 31, 2024, an estimated **$460.5 million of net proceeds from the IPO remained**, which have been invested in investment-grade, interest-bearing instruments[131](index=131&type=chunk) | Period | Total Number of Shares Repurchased | Average Price Paid per Share | Approximate Dollar Value of Shares that May Yet Be Repurchased (in thousands) | | :--- | :--- | :--- | :--- | | March 1 - 31, 2024 | 21,329,492 | $7.26 | $295,185 | [Defaults Upon Senior Securities](index=22&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - None[134](index=134&type=chunk) [Mine Safety Disclosures](index=22&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company's operations - Not applicable[135](index=135&type=chunk) [Other Information](index=22&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading plans during the first quarter of 2024 - During the three months ended March 31, 2024, **none of the company's directors or officers adopted or terminated** any contract, instruction or written plan for the purchase or sale of securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)[136](index=136&type=chunk) [Exhibits](index=23&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including agreements and certifications

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise.Over the last four quarters, the company ha ...

Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Exhibit 99.1 Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million. Prescription transactions revenue increased 8% to $145.4 million compar ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9. The analyst in coverage cited the potential for strong subscriber growth, as well as a positive shift in the company's monthly active users (MAUs). GoodRx  jumped nearly 4% premarket, but broad market headwinds are capping gains. The stock has support at its 80-day moving average, which has propped u ...

GoodRx Holdings, Inc. (GDRX) closed the last trading session at $6.77, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.74 indicates a 29.1% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $2.19. While the lowest estimate of $5 indicates a 26.1% decline from the current price level, the most optimistic analyst exp ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company’s Board of Directors, effective March 14, 2024 and March 22, 2024, respectively. “I’m encouraged by the progress the team is making and happy to see the hard work start showin ...

GoodRx Holdings, Inc. (GDRX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate re ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

GoodRx Holdings, Inc. (GDRX) reported $196.64 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.8%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $195.59 million, representing a surprise of +0.54%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.08.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...